Gitika Sharma l Oral pathology | Research Excellence Award

Published on by Research Data Analysis

Assist. Prof. Dr. Gitika Sharma l Oral pathology | Research Excellence Award

Sudha rustagi college of dental sciences and research | India

Assist. Prof. Dr. Gitika Sharma is an oral pathologist and academic researcher with strong training in diagnostic pathology, molecular research, and undergraduate teaching. She holds BDS and MDS degrees in Oral Pathology and has professional experience as junior resident, senior resident, and faculty, with extensive involvement in teaching and academic mentoring. Her research interests focus on oral squamous cell carcinoma, salivary gland tumors, immunohistochemistry, molecular diagnostics, cell culture, and drug testing. Her research skills include histopathological evaluation, ELISA, immunohistochemistry, systematic reviews, meta-analysis, and scientific writing, supported by numerous peer-reviewed publications and a scholarly book, reflecting sustained contributions to oral pathology research and clinical diagnostics.

Citation Metrics (Scopus)

200
150
100
50
0

Citations
46

Documents
19

h-index
4

Citations

Documents

h-index


View Scopus Profile View Orcid Profile

Featured Publications

Erika Azorin-vega | Qualitative Research | Women Researcher Award

Published on by Research Data Analysis

Dr. Erika Azorin-vega | Qualitative Research | Women Researcher Award

Instituto Nacional De Investigaciones Nucleares | Mexico

Erika Patricia Azorín Vega is a distinguished researcher at the Instituto Nacional de Investigaciones Nucleares, specializing in radiopharmaceuticals and their applications in cancer diagnosis and therapy. She holds a Bachelor’s degree in Experimental Biology from Universidad Autónoma Metropolitana-Iztapalapa, a Master’s in Sciences, and a Ph.D. in Bio-Physiology and Neurosciences from CINVESTAV-IPN, with research focused on cellular interactions with extracellular matrices and tumor cell biology. Since 2013, she has led pioneering work in radiopharmaceutical development, resulting in four international patents and over 80 scientific publications with nearly a thousand citations. Her academic contributions include directing multiple undergraduate and graduate theses, reviewing projects for national and international funding agencies, and participating in thesis evaluations globally. She has served as a professor and invited lecturer at several universities, delivering specialized courses in radiobiology, dosimetry, and medical physics, both nationally and internationally. Her research interests encompass radiopharmaceutical design, cancer radiotherapy, metabolomics, and radiation protection. Recognized for her excellence in scientific communication, she has delivered numerous conferences and outreach presentations to advance knowledge in nuclear medicine. Erika’s work continues to shape the field of radiopharmaceutical research and the training of highly skilled professionals in medical physics and biotechnology.

Profile : Google Scholar

Featured Publications

Jiménez-Mancilla, N., Ferro-Flores, G., Santos-Cuevas, C., & et al. (2013). Multifunctional targeted therapy system based on 99mTc/177Lu-labeled gold nanoparticles-Tat(49–57)-Lys3-bombesin internalized in nuclei of prostate cancer. Journal of Labelled Compounds and Radiopharmaceuticals, 56(13), 663–671.

Ferro-Flores, G., Luna-Gutiérrez, M., Ocampo-García, B., Santos-Cuevas, C., & et al. (2017). Clinical translation of a PSMA inhibitor for 99mTc-based SPECT. Nuclear Medicine and Biology, 48, 36–44.

Mendoza-Nava, H., Ferro-Flores, G., Ramírez, F. M., Ocampo-García, B., & et al. (2016). 177Lu-dendrimer conjugated to folate and bombesin with gold nanoparticles in the dendritic cavity: A potential theranostic radiopharmaceutical. Journal of Nanomaterials, 2016(1), 1039258.

Azorín-Vega, A. V. E., Ferro-Flores, G., & Ocampo-García, B. E. (2014). Multifunctional radiolabeled nanoparticles for targeted therapy. Current Medicinal Chemistry, 21(1), 124–138.

Mendoza-Nava, H., Ferro-Flores, G., Ramírez, F. M., Ocampo-García, B., & et al. (2017). Fluorescent, plasmonic, and radiotherapeutic properties of the 177Lu–dendrimer-AuNP–folate–bombesin nanoprobe located inside cancer cells. Molecular Imaging, 16, 1536012117704768.

Hillary Andrews | Data Analysis | Best Researcher Award

Published on by Research Data Analysis

Dr. Hillary Andrews | Data Analysis | Best Researcher Award

Friends of Cancers Research | United States

Dr. Hillary S. Andrews, PhD, is a project leader and policy researcher whose scholarly output reflects strong engagement in cancer research regulation, patient-advocacy partnerships, and translational biomarker work. According to Google Scholar, she has an h-index of 7, with about 395 citations across her publications. She earned her PhD in Endocrinology and Animal Biosciences (Rutgers University, 2016), followed by a T32 NRSA postdoctoral fellowship in Tumor Biology at Georgetown University’s Lombardi Comprehensive Cancer Center. In her professional experience, she has held roles at Avalere Health (Consultant / FDA Fellow), then at Friends of Cancer Research, where she is now Director of Regulatory & Research Partnerships (since Dec 2022), after serving as Science Policy Analyst. Her work includes leading research partnerships like ctMoniTR and the HRD Harmonization Project, developing policy, authoring white-papers and peer-reviewed articles, and presenting findings at international meetings. Her research interests center on regulatory policy in oncology, translational biomarkers (e.g. HRD, circulating tumor DNA), patient access, market access pathways, and partnerships between patient advocates and researchers. Among her recognitions is authorship in high-visibility policy reports and scientific collaborations that bridge stakeholders (e.g. regulators, academia, patient advocates). In conclusion, her career demonstrates a consistent track record of integrating research, regulation, and stakeholder engagement to accelerate patient-centered cancer research and policy.

Profiles : Orcid | Google Scholar

Featured Publications

“Analysis of 20 Independently Performed Assays to Measure Homologous Recombination Deficiency (HRD) in Ovarian Cancer: Findings From the Friends’ HRD Harmonization Project”

“Advancing Evidence Generation for Circulating Tumor DNA: Lessons Learned from A Multi-Assay Study of Baseline Circulating Tumor DNA Levels across Cancer Types and Stages”

“An Analysis of Dosing-Related Postmarketing Requirements for Novel Oncology Drugs Approved by the U.S. Food and Drug Administration, 2012–2022”

“Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer”

“Sponsor Perspectives on the Impact of the COVID-19 Pandemic on Interventional Cancer Clinical Trial Protocols and Data Quality”